Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study

Not yet recruitingOBSERVATIONAL

Enrollment

460

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

November 1, 2027

Study Completion Date

November 1, 2029

Conditions

Mycosis Fungoides/Sezary SyndromeCutaneous T Cell Lymphoma

Interventions

OTHER

Follow-up

Clinical evaluation Blood sample Skin biopsy

All Listed Sponsors

lead

Assistance Publique - Hôpitaux de Paris

OTHER